Dr. Rosenblatt’s career has been in academia, the pharmaceutical industry and biotech/venture. He is a physician, scientist, educator and leader in healthcare. He currently serves as Chief Medical Officer of Flagship Pioneering in Cambridge, MA, a venture firm that creates new life science companies. He was Executive Vice President and Chief Medical Officer for Merck from 2009-2016. Previously he was Dean, Tufts University School of Medicine. Prior to that, he was Robert Ebert Professor of Molecular Medicine and then George R. Minot Professor of Medicine at Harvard Medical School. He was President of Beth Israel Deaconess Medical Center (BIDMC) from 1999-2001, and earlier Director of the Harvard-MIT Division of Health Sciences and Technology and Senior VP for Research at Merck where he co-led worldwide development of alendronate (FOSAMAX) for osteoporosis. Before joining Merck the first time, he was Chief of the Endocrine Unit at the Massachusetts General Hospital.
Dr. Rosenblatt has been active in the biotechnology industry, serving on the board of directors and scientific advisory boards of several biotech companies. He was a scientific founder of ProScript, which discovered bortezomib (Velcade) for multiple myeloma, and Radius Pharmaceuticals, a company that has developed abaloparatide (TYMLOS) for osteoporosis.
He currently is on the Harvard Medical School Board of Fellows, and research advisory committees of the Massachusetts General Hospital, Brigham and Women’s Hospital, and Children’s Hospital (Boston).
Dr. Rosenblatt received his undergraduate degree summa cum laude from Columbia and his M.D. magna cum laude from Harvard. His internship, residency, and endocrinology training were all at the Massachusetts General Hospital.